Oxeia Biopharmaceuticals

Executive Summary

Oxeia Biopharmaceuticals is a private clinical-stage biotech company focused on developing the first FDA-approved therapy for persistent symptoms following mild traumatic brain injury (mTBI), also known as concussion. Its lead candidate, OXE103, is a novel small molecule that has completed a Phase 2a trial, demonstrating a strong treatment effect. The company seeks to address a significant unmet medical need, as there are currently no approved pharmacological treatments for persistent concussion symptoms. With encouraging Phase 2a data, Oxeia is preparing for later-stage development, positioning itself for potential regulatory milestones and value creation. The company's focused strategy and promising clinical data support its potential to become a leader in the mTBI therapeutic space.

Upcoming Catalysts (preview)

• H2 2026Initiation of Phase 2b/3 pivotal trial70% success
• Q3 2026FDA meeting to discuss Phase 3 design80% success
• 2026Potential partnership or licensing agreement50% success